

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**ALPHAMAB ONCOLOGY**

**康寧傑瑞生物製藥**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9966)**

## **VOLUNTARY ANNOUNCEMENT**

### **FIRST PATIENT DOSED IN A PHASE I CLINICAL TRIAL OF JSKN003 (KN026-ADC) IN AUSTRALIA FOR THE TREATMENT OF ADVANCED SOLID TUMORS**

This announcement is made by Alphas Mab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the “**Directors**”) of the Company (the “**Board**”) is pleased to announce that the first patient has been successfully dosed in a phase I clinical trial of JSKN003 (a KN026 (a recombinant humanized anti-human epidermal growth factor receptor 2 (“**HER2**”) bispecific antibody) antibody-drug conjugate (“**KN026-ADC**”) independently developed by the Company) in Australia. This clinical trial is an open-label, multi-center, dose-escalation phase I clinical trial designed to evaluate the safety, tolerability and preliminary efficacy of JSKN003 as well as to determine the recommended phase II dose (RP2D) of JSKN003 in the treatment of advanced solid tumors.

#### **ABOUT JSKN003**

JSKN003 is a biparatopic HER2-targeting ADC, of which a topoisomerase I inhibitor is linked to the N glycosylation site of the antibody KN026 (a next-generation anti-HER2 bispecific antibody that can simultaneously bind two distinct clinically-validated epitopes of HER2, resulting in potentially superior efficacy) via the glycosite-specific conjugation. The click reaction based conjugation confers better serum stability than maleimide-Michael reaction-based conjugation. The biparatopic HER2-targeting enables JSKN003 to have stronger internalization induction and bystander killing effect leading to potent antitumor activity in HER2 expression tumors with the mild toxicity drug payload. A phase I clinical trial is currently undergoing in Australia. And in August 2022, the investigational new drug (“**IND**”) application of JSKN003 was submitted to the National Medical Products Administration of China (the “**NMPA**”) and accepted for the treatment of solid tumors.

## **ABOUT THE COMPANY**

The Company is a leading biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecific and protein engineering. Differentiated in-house clinical pipeline of the Company includes the oncology drug candidates with one approved for marketing by the NMPA, three in late clinical stage and two in phase I clinical trial stage. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological new drug candidates that could potentially benefit patients globally.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that it will be able to develop, or ultimately market JSKN003 and KN026, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board  
**Alphamab Oncology**  
**Dr. XU Ting**  
*Chairman and Executive Director*

Hong Kong, September 19, 2022

*As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin as Non-executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.*